Clinical Trials
Please check with your doctor or call 301-754-7552 to find out if you qualify for any of these studies.
Breast Cancer
Trial #: D8531C00002 CAMBriA-1
Sponsor: AstraZeneca
Trial Sub-Type: HR+/HER2- early breast cancer
Title and Key Inclusion/Exclusion Criteria: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Switching to AZD9833 (a Next Generation, Oral SERD) vs Continuing Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patients with HR+/HER2- early breast cancer and a intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine therapy without disease recurrence (CAMBriA-1)
Trial #: NSABP B-64 COMING SOON!
Sponsor: Exact Sciences /NSABP Foundation
Trial Sub-Type: Patients with newly diagnosed breast cancer treated with neoadjuvant therapy
Title and Key Inclusion/Exclusion Criteria: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
Trial #: MK-2870-012 COMING SOON!
Trial Sub-Type: TNBC treated with neoadjuvant therapy and did not achieve a pathological response
Sponsor: MERCK
Title and Key Inclusion/Exclusion Criteria: A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery
Trial #: MK-2870-01 COMING SOON!
Trial Sub-Type: HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Sponsor: MERCK
Title and Key Inclusion/Exclusion Criteria: An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Trial #: D9722C00001 EvoPAR-Breast01 COMING SOON!
Sponsor: Astra Zeneca
Trial Sub-Type: BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2 Negative Advanced Breast Cancer
Title and Key Inclusion/Exclusion Criteria: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2 Negative (IHC 0, 1+, 2+/ ISH non amplified) Advanced Breast Cancer (EvoPAR-Breast01)
GYN Cancer
Trial #: Olvi-Vec-022
Sponsor: Genelux Corporation. / GOG 3076
Trial Sub-Type: Platinum-Resistant/Refractory Ovarian Cancer
Title and Key Inclusion/Exclusion Criteria: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer
Trial #: ACR-368-201
Sponsor: Acrivon Therapeutics, Inc/ GOG-3082
Trial Sub-Type: Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Title and Key Inclusion/Exclusion Criteria: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
Trial #: BP1001-A-101-GynOnc Phase I
Trial Sub-Type: Recurrent or persistent epithelial ovarian, primary peritoneal, fallopian tube cancer
Sponsor: Bio-Path Holdings, Inc
Title and Key Inclusion/Exclusion Criteria: BP1001-A-101-GynOnc: A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients with Advanced or Recurrent Solid Tumors.
Trial #: AOA-PRT-0001
Trial Sub-Type: Suspicion, signs, or symptoms suggestive of ovarian cancer
Sponsor: AOA Dx, Inc.
Title and Key Inclusion/Exclusion Criteria: Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
Trial #: IMGN853-0424
Sponsor: ImmunoGen, Inc.
Trial Sub-Type: Recurrent Ovarian Cancer
Title and Key Inclusion/Exclusion Criteria: A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
Trial #: DB-1303/BNT323 COMING SOON!
Sponsor: DUALITYBIO INC
Trial Sub-Type: Advanced/Mestastic Solid Tumors
Title and Key Inclusion/Exclusion Criteria: A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors
Lung Cancer
Trial #: CGME751A12301
Sponsor: Hexal AG and Sandoz Inc.
Trial Sub-Type: Patients with untreated metastatic non-squamous non-small cell lung cancer
Title and Key Inclusion/Exclusion Criteria: A randomized, double-blind, parallel-group study to compare efficacy, safety, and immunogenicity of GME751 (proposed pembrolizumab biosimilar) and EU-authorized Keytruda® in adult participants with untreated metastatic non-squamous non-small cell lung cancer (NSCLC)
Trial #: D9075C00001 (PACIFIC-8)
Sponsor: Astra Zeneca
Trial Sub-Type: (Stage III), Unresectable Non-small Cell Lung Cancer
Title and Key Inclusion/Exclusion Criteria: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based
Concurrent Chemoradiation Therapy (PACIFIC-8)
Trial #: D967SC00001 (DESTINY - Lung04)
Sponsor: Astra Zeneca
Trial Sub-type: Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations
Title and Key Inclusion/Exclusion Criteria: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)
Trial #: D5162C00048 TARGET
Sponsor: Astra Zeneca
Trial Sub-type: Stage II-IIIB Non-small Cell Lung Carcinoma, EGFR positive
Title and Key Inclusion/Exclusion Criteria: An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation-Positive Stage II-IIIB Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (TARGET)